- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05518682
Assessment of Bimodal Stimulation Device Compliance and Satisfaction in Individuals With Tinnitus
The research objective of the proposed usability study is to assess the compliance and acceptance/satisfaction of using a bimodal stimulation device with the ability to self-adjust the sound stimulus presented to the ears via headphones. In particular, the CE marked bimodal stimulation portable device, Lenire, which is developed by Neuromod Devices Limited (Dublin, Ireland) to alleviate the symptoms of chronic subjective tinnitus, is currently configured according to a tinnitus person's audiogram (i.e., hearing threshold profile for different sound frequencies) during fitting in a hearing center. Lenire device is a non-invasive stimulation device that consists of a controller that connects to headphones for sound delivery to the ears and connects to a mouth component that provides gentle electrical stimulation to the tongue surface. Individuals are recommended to use the device for 60 minutes daily (two 30-minute sessions consecutively or at different times of the day) for at least 10 weeks. Lenire is already commercialized across Europe and available by audiologists or hearing technicians in numerous hearing centers for treating tinnitus. It has also been evaluated in two large-scale clinical trials in over 500 tinnitus participants, demonstrating tinnitus benefit and minimal risk with high compliance and satisfaction rates.
The primary objective of the proposed usability study is to first assess compliance and satisfaction with the Lenire device that does not require an audiogram for fitting and that can be implemented mostly through virtual visits (except for the first visit). These modifications to the Lenire fitting process will reduce the time and personnel effort required for its implementation, enabling a broader patient population to access bimodal stimulation for tinnitus treatment, including military personnel and those who are not nearby hearing centers for in-person sessions. High compliance and satisfaction rates from this small proof-of concept usability study will then justify and guide a larger clinical study to assess efficacy and performance of this newly implemented Lenire device process.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Yezihalem Mesfin, MSE
- Phone Number: 612-626-4565
- Email: TinnitusUMN@umn.edu
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota - TESSLab/PWB
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18 years and over at time of consent
- Ability to read and understand English
- Willing and able to provide and understand informed consent
- Willing to commit to the full duration of the investigation
- Subjective tinnitus
- Tinnitus duration of greater than or equal to 3 months and less than or equal to 20 years at time of consent
- Baseline THI score from 38 to 76
- Hearing loss condition (low hearing loss group (n=10) and high hearing loss group (n=10))
- Access to reliable internet connection and device to complete virtual video visits and electronic surveys
Exclusion Criteria:
- Subjective tinnitus, where pulsatility is the dominant feature
- Objective tinnitus
- Middle ear pathology in either ear including documented/known conductive hearing loss >= 20 dB at three adjacent frequencies or if a diagnosis of a tympanic membrane perforation or other middle ear pathology has been rendered, if there is an indwelling pressure equalization tube by patient report, or if middle ear surgery has been performed
- Began wearing hearing aids within the past 3 months
- Health care provider has rendered a diagnosis of Meniere's disease or other disorder with fluctuating hearing loss
- A diagnosis of hyperacusis, misophonia or hypersensitivity to loud noises has been rendered
- History of auditory hallucinations
- Tumor on the hearing or balance nervous systems
- Hospitalization, or visit to a physician, for a head or neck injury, including whiplash, in the previous 12 months
- Initiated new prescription medications or medical treatments in the previous 3 months that may impact the outcomes of the investigation, based on class of medication: antidepressants, anticonvulsants, neuroleptics and opioid analgesics. See Appendix 2 for list of medical treatments.
- Ceased prescription medications or medical treatments in the previous 3 months that may impact the outcomes of the investigation, based on class of medication: antidepressants, anticonvulsants, neuroleptics and opioid analgesics. See Appendix 2 for list of medical treatments.
- Changed dosage of prescription medications in the previous 3 months that may impact the outcomes of the investigation, based on class of medication: antidepressants, anticonvulsants, neuroleptics and opioid analgesics. See Appendix 2 for list of medical treatments.
- Any use of benzodiazepines or sedative hypnotics (either regularly or on demand)
- Neurological condition that may lead to seizures or loss of consciousness (e.g., epilepsy)
- Participant with a pacemaker or other electro-active implanted device
- Participant previously diagnosed with psychosis or schizophrenia
- Participants diagnosed with Burning Mouth Syndrome
- A diagnosis of bothersome temporomandibular joint disorder (TMJ) has been rendered
- Previous involvement in a clinical investigation for tinnitus treatment or had an implantable or surgical intervention for tinnitus
- Inability to physically or comprehensively use the device
- Oral piercings that cannot or will not be removed
- Current or previous involvement in medico-legal cases
- Pregnancy per patient report
- Prisoner
- PI does not deem the candidate to be suitable for the investigation for other reasons not listed above. Rationale must be provided.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single study arm
The Lenire device is CE marked in Europe and intended to reduce the symptoms of tinnitus.
It comprises a handheld controller and an intra-oral device called a Tonguetip® Intra-Oral Device (IOD), which delivers gentle electrical stimulation to the tongue, and also comprises of a set of wireless consumer headphones that deliver audio stimulation.
The sound and tongue stimulus parameters such as stimulus rate, stimulus intensity, and the timing relationship between the auditory and somatosensory stimulus events are grouped into stimulation Parameter Sets (PS).
PS1 is used during the first 6-weeks of stimulation and PS4 is used during the second 6-weeks of stimulation, similar to what is routinely used for tinnitus individuals in Europe.
For this study, the device software has been modified to allow users to adjust the headphone volume to a level that is comfortable and clearly audible instead of a preset volume with limited adjustments based on the patient's audiogram.
|
The sound and tongue stimulus parameters such as stimulus rate, stimulus intensity, and the timing relationship between the auditory and somatosensory stimulus events are grouped into stimulation Parameter Sets (PS).
PS1 is used during the first 6-weeks of stimulation and PS4 is used during the second 6-weeks of stimulation, similar to what is routinely used for tinnitus individuals in Europe.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compliance rate after 12 weeks of bimodal stimulation
Time Frame: Enrollment visit to week 12 visit (end of device stimulation)
|
Compliance rate after 12 weeks of bimodal stimulation with minimum compliance of a total of 36 hours
|
Enrollment visit to week 12 visit (end of device stimulation)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Satisfaction rate after 12 weeks of bimodal stimulation
Time Frame: Enrollment visit to week 12 visit (end of device stimulation)
|
Satisfaction rate (two satisfaction questions) after 12 weeks of bimodal stimulation
|
Enrollment visit to week 12 visit (end of device stimulation)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Impact of the stimulation device on tinnitus symptoms after 12 weeks of bimodal stimulation
Time Frame: Enrollment visit to week 12 visit (end of device stimulation) and 12 week follow-up visit
|
Tinnitus Handicap Inventory (THI)
|
Enrollment visit to week 12 visit (end of device stimulation) and 12 week follow-up visit
|
Impact of the stimulation device on tinnitus symptoms after 12 weeks of bimodal stimulation
Time Frame: Enrollment visit to week 12 visit (end of device stimulation) and 12 week follow-up visit
|
Tinnitus Functional Index (TFI)
|
Enrollment visit to week 12 visit (end of device stimulation) and 12 week follow-up visit
|
Impact of the stimulation device on tinnitus symptoms after 12 weeks of bimodal stimulation
Time Frame: Enrollment visit to week 12 visit (end of device stimulation) and 12 week follow-up visit
|
Visual Analog Scale for Loudness (VAS-L)
|
Enrollment visit to week 12 visit (end of device stimulation) and 12 week follow-up visit
|
Impact of the stimulation device on health after 12 weeks of bimodal stimulation
Time Frame: Enrollment visit to week 12 visit (end of device stimulation)
|
Patient Health Questionnaire (PHQ-8)
|
Enrollment visit to week 12 visit (end of device stimulation)
|
Impact of the stimulation device on stress after 12 weeks of bimodal stimulation
Time Frame: Enrollment visit to week 12 visit (end of device stimulation)
|
Perceived Stress Scale (PSS-10)
|
Enrollment visit to week 12 visit (end of device stimulation)
|
Impact of the stimulation device on anxiety after 12 weeks of bimodal stimulation
Time Frame: Enrollment visit to week 12 visit (end of device stimulation)
|
Generalized Anxiety Disorder (GAD-7)
|
Enrollment visit to week 12 visit (end of device stimulation)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Meredith Adams, MD, University of Minnesota
- Principal Investigator: Peggy Nelson, PhD, University of Minnesota
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00015524
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tinnitus
-
State University of New York at BuffaloUniversity at BuffaloCompletedTinnitus, Subjective | Tinnitus | Noise Induced Tinnitus | Tinnitus, Objective | Tinnitus Aggravated | Tinnitus, Pulsatile | Tinnitus, Spontaneous Oto-Acoustic Emission | Tinnitus, Clicking | Tinnitus, Tensor Tympani InducedUnited States
-
Mohab MohammedNot yet recruitingPulsatile Tinnitus (Diagnosis)
-
Philipps University Marburg Medical CenterLinkoeping University; Eriksholm Research Centre; University Hospital of Gießen...CompletedTinnitus | Subjective Tinnitus | Chronic TinnitusGermany
-
University of GuadalajaraHospital Civil de Guadalajara; Institute of Experimental and Clinical TherapeuticsRecruitingOxidative Stress | Tinnitus, Subjective | Tinnitus, Bilateral | Antioxidant Therapy | Psychiatric Drugs | Inflammatory Cytokines | SSRIMexico
-
University Hospital, BordeauxNot yet recruiting
-
Cairo UniversityRecruiting
-
University of ZurichRecruitingTinnitus, Subjective | TinnitusSwitzerland
-
Eye & ENT Hospital of Fudan UniversityNot yet recruiting
-
University of Illinois at Urbana-ChampaignGN Hearing A/SActive, not recruitingTinnitus, SubjectiveUnited States
-
University of ZurichCompletedTinnitus, SubjectiveGermany, Switzerland
Clinical Trials on Lenire bimodal stimulation device
-
Neuromod Devices Ltd.BRAI3N (clinical site), Belgium; St James's Hospital (clinical site), Ireland; German Hearing Center Hannover (clinical site), Germany and other collaboratorsCompletedTinnitusBelgium, Germany, Ireland
-
University of MichiganWallace H Coulter Center for Translational ResearchCompleted
-
Neurolief Ltd.Terminated
-
Neurolief Ltd.Completed
-
University of British ColumbiaUnited States Department of DefenseNot yet recruitingSpinal Cord Injuries | Autonomic DysfunctionCanada
-
EMKinetics, IncTerminated
-
Seoul National University HospitalRecruitingDysphagiaKorea, Republic of
-
Seoul National University HospitalCompleted
-
Northwestern UniversityEvergreen InvitationalCompletedObstetric Anal Sphincter Injury | Vaginal Electrical StimulationUnited States
-
University of ManchesterManchester University NHS Foundation Trust; Firstkind LtdUnknown